Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Targeted Therapies in Advanced Cancers Based on Genomic Alterations
NCT02795156Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Sep 2016
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of afatinib, regorafenib, cabozantinib in non-small cell lung cancer (NSCLC), urothelial carcinoma (UC), gastrointestinal cancer, head and neck cancer (HNC), sponsored by SCRI Development Innovations. Started Sep 2016; status: completed.
02
Drugs
afatinibregorafenibcabozantinib
03
Conditions
non-small cell lung cancer (NSCLC)urothelial carcinoma (UC)gastrointestinal cancerhead and neck cancer (HNC)
Beyond the preview
Go deeper on NCT02795156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02795156.